莎普爱思(603168.SH)：硫酸特布他林雾化吸入用溶液完成药品注册

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its nebulized solution of Terbutaline Sulfate, which is intended to alleviate bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The approved product is a nebulized solution of Terbutaline Sulfate [1] - The solution is indicated for the relief of bronchial asthma and other respiratory conditions [1]